Synthesis and Biological Evaluations of Ring Substituted Tetrahydroisoquinolines (THIQs) as Anti-Breast Cancer Agents

Suresh VK Eyunni¹, Madhavi Gangapuram¹, Bereket Mochona², Nelly Mateeva², and Kinfe K Redda¹,*

¹College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, USA
²College of Science and Technology, Florida A&M University, Tallahassee, FL-32307, USA

Abstract

Breast cancer is a leading cause of mortality among women, resulting in more than half a million deaths worldwide every year. Although chemotherapeutic drugs remain the mainstay of cancer treatment, it is observed that toxicity to normal cells poses a limitation to their therapeutic values. Moreover, the patient recovery rate from advanced breast cancer by chemotherapy is still unacceptably low. Tetrahydroisoquinoline derivatives (THIQs) were reported to act as selective subtype estrogen receptor antagonists/agonists and may serve as potential therapeutic agents for breast cancer. In continuation of previous work we systematically synthesized and characterized the tetrahydroisoquinoline (THIQs) analogs. In-vitro antiproliferative activity of new substituted tetrahydroisoquinoline analogs were evaluated against human ER (+) MCF-7 (breast), ER (−) MDA-MB-231 (breast) and Ishikawa (endometrial) cancer cell lines using the CellTiter-Glo luminescent cell viability assay. The most active compounds obtained in this study were 2b, 2i, and 3g as demonstrated by their activity (IC₅₀ = 0.2 μg/mL, 0.08 μg/mL; 0.61 μg/mL, 0.09 μg/mL; 0.25 μg/mL, 0.11 μg/mL) against MCF-7 and Ishikawa cell lines respectively, in comparison to Tamoxifen activity (IC₅₀ = 3.99 μg/mL, 7.87 μg/mL). The newly synthesized molecules were docked in the active sites of the ER-α (PDB: 3ERT), ER-β (PDB: 1QKN) and alpha-beta tubulin taxol complex (1JFF) crystal structures to determine the probable binding modes (bioactive conformations) of the active compounds.

Keywords

Ring substituted tetrahydroisoquinolines (THIQs); Antiproliferative activity; Breast cancer

Introduction

Breast cancer is considered to be one of the leading causes of cancer-related deaths in women in United States. An estimated 252,710 new cases of invasive breast cancer are expected to be diagnosed in women in the USA, along with 63,410 new cases of non-
invasive (in situ) breast cancer in the year 2017 [1]. Estrogen Receptor (ER), Progesterone Receptor (PR) and their associated steroid hormones play an important role in the development, differentiation and function of normal breast and endometrial cells. Endocrine therapy is usually offered after post-surgery and radiotherapy for breast cancer patients. In breast cancer studies, the role of ER is an endocrine therapy efficacy predictor whereas PR’s role is unknown [2]. The two subtypes of human ER, ER-α and ER-β display different tissue distribution patterns and transcriptional activities. Blocking estrogen (E2) binding to ER receptors in ER+ve breast cancer cells by employing active inhibitors of ER, stalls the growth and multiplication of cancer cells. Hence, ER-α and ER-β remain attractive targets in the treatment of breast cancer as they are over expressed in breast cancer cells. In this regard, a steroid structure based, highly Selective Estrogen Receptor Degrader (SERD) like fulvestrant, inhibit estrogen signaling process through the ER by acting as an antagonist to the estradiol binding to the ER and decreasing the ER level in breast cancer cells [3–7]. In contrast, tamoxifen (TAM), a selective ER modulator (SERM) is non-steroidal ER antagonist and often displays undesired estrogen-like agonist activity in other tissues [8–10]. Attaching various substituents on the steroidal skeletal structure of E2 resulted in a number of marketed drugs used in the treatment of hormone-dependent breast cancer [11–14]. However, steroid based anti-breast cancer agents are risk prone to other organs and display adverse side effects. TAM has been the leading drug in treating breast cancer for more than two decades and has proven to be an effective treatment for ER (+) breast cancer, particularly in the post-menopausal women [15–18]. The limitation of TAM is that, it behaves as ER antagonist in the breast tissue and as an ER agonist in other tissues with increased risk of developing endometrial cancer [19,20].

Compounds possessing tetrahydroisoquinoline (THIQ) core structure were recently reported to be effective and selective estrogen receptor modulators and have the potential of being the therapeutic agents for treating breast cancer [21,22]. Structure activity relationship studies (SAR) of ER-α selective THIQs and THIQs incorporating rigid and conformationally restricted side chains were reported by Renaud et al. [23,24]. Natural or synthesized THIQs are known to exert antiproliferative effects on cancer cells by inducing cell cycle arrest at G2/M phase [25–28]. New steroidomimetic THIQs were also reported, to act as microtubule disruptors [29]. In this regard, we also recently reported the synthesis of our most effective cytostatic THIQ compounds, which blocked replicative processes at the G2 growth phase. They proved to be effective in halting proliferation without any observed toxicity. These findings appear to suggest that some specific THIQs might work independently of the ER, e.g., by holding the microtubule network static, thereby preventing mitosis [30].

In our recent studies [31], we reported the most potent substituted THIQ 1, as the lead structure. Here we report the synthesis of new ring substituted THIQs and their in-vitro antiproliferative activities were tested against MCF-7, MDA-MB-231 human breast cancer cell lines and Ishikawa human endometrial adenocarcinoma cell lines. Tamoxifen (TAM), Raloxifene (RAL) and 4-Hydroxytamoxifen (4-OHT) were used as reference compounds. In-silico docking analysis and probable binding modes of these compounds were determined by mapping the active sites of the ER-α-4-OHT complex (PDB: 3ERT), ER-β-RAL complex (PDB: 1QKN), and α-β Tubulin-Taxol complex (PDB: 1JFF).
Materials and Methods

Experimental section

General—Melting points were determined on a mel-temp 3.0 melting point apparatus and are uncorrected. The structures of the final compounds were confirmed by $^1$HNMR and elemental analysis. The spectra were recorded on Varian Gemini HX 300 MHz spectrometer. All chemical shifts expressed in parts per million (δ, ppm) are reported relative to tetramethylsilane (TMS) as internal standard for solution in CDCl$_3$ as a solvent unless otherwise specified. Elemental analysis of the final compounds were performed by Atlantic Microlab Inc., Norcross, GA. Flash chromatography was performed on CombiFlash (Teledyne Isco) using RediSep columns. All chemicals and solvents were purchased from Sigma-Aldrich and were used without further purification.

General procedure (Scheme 1) synthesis of substituted tetrahydroisoquinolinium-2,4,6-trimethyl benzene sulfonate (11a-11m)—O-mesitylene sulfonyl hydroxylamine (MSH) (10) was used to prepare the N-amino salt as an aminating agent [32] as previously reported [31]. To an ice-cooled solution of substituted isoquinolines (20.67 mmol) in anhydrous methylene chloride and anhydrous methanol (1:1) (60 mL) was added MSH (10) (22.74 mmol) in dry methylene chloride (10 mL) over 5 min with stirring. The reaction was stirred at 0°C for 6 h at which time ether (80 mL) was added and the suspension filtered. The precipitate was recrystallized from ethyl acetate-methanol (5:1 v/v) to give substituted isoquinolinium, 2,4,6-trimethylbenzene-sulfonate salts (11a–11m) in high yields.

General procedure for acylation leading to ylides (12a–12m)—To an ice-cold solution of (11a–11m) (4.16 mmol) in anhydrous tetrahydrofuran (40 mL), containing triethylamine were added substituted acid chlorides (8.34 mmol). The mixture was allowed to proceed for 12 h at 70°C. After the completion of the reaction (monitored by TLC), it was quenched by adding 30 mL of saturated aqueous sodium bicarbonate solution. Extraction with dichloromethane (3 mL × 100 mL), drying over anhydrous sodium sulfate and removal of the solvent in vacuo gave the crude product, which was purified on CombiFlash chromatography using ethyl acetate: hexane (3:2 v/v) mixture as eluent. The resultant mono N-acylated ylides were obtained in fair to good yields.

General procedure for reduction yielding the substituted tetrahydroisoquinolines (2a–2m)—The Ylides (11a–11m) (5 mmol) were dissolved in absolute ethanol (20 mL) and added drop-wise to a solution of sodium borohydride (50 mmol) in absolute ethanol (25 mL) at 0°C. The reactions were allowed to proceed for 5 h to 7 h at the same. Water (35 mL) was added, and allowed to warm up to room temperature. Extraction with dichloromethane (3 mL × 50 mL), drying over anhydrous sodium sulfate and removal of the solvent in vacuo gave the desired products. All substituted tetrahydroisoquinolines were purified on CombiFlash using ethyl acetate: dichloromethane (2:3 v/v) as eluent to afford pure compounds (2a–2m) in fair to good yields.
N-(5-bromo-3,4-dihydroisoquinol in-2(1H)-yl)-4-ethylbenzamide (2a)—Yield 65%; m.p. 192°C to 193°C; $^1$HNMR (CDCl$_3$) $\delta$ (ppm): 7.65 (d, $J=8.1$ Hz, 2H), 7.17 (d, $J=8.1$ Hz, 2H), 7.09 (s, 1H, -NH, D$_2$O exchange), 6.79 (d, $J=8.4$ Hz, 1H), 6.58 (dd, $J=2.7,5.4$ Hz, 1H), 6.35 (d, $J=2.1$, 1.8 Hz, 1H), 3.94 (s, 2H), 3.18 (t, $J=5.7$ Hz, 2H), 2.86 (t, $J=6.0$ Hz, 2H), 2.64--2.72 (q, $J=7.5$ Hz, 2H), 1.18 (t, $J=7.5$ Hz, 3H). Anal. Calcd. for C$_{18}$H$_{19}$BrN$_2$O (359.26): C 60.18; H 5.33; N 7.80. Found: C 60.07; H 5.52; N 7.68.

4-Ethyl-N-(7-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl) benzamide (2b)—Yield 65%; m.p. 202.3°C to 203.5°C; $^1$HNMR (CDCl$_3$) $\delta$ (ppm): 7.65 (d, $J=8.1$ Hz, 2H), 7.17 (d, $J=8.1$ Hz, 2H), 7.09 (s, 1H, -NH, D$_2$O exchange), 6.79 (d, $J=8.4$ Hz, 1H), 6.58 (dd, $J=2.7,5.4$ Hz, 1H), 6.35 (d, $J=2.1$, 1.8 Hz, 1H), 3.94 (s, 2H), 3.18 (t, $J=5.7$ Hz, 2H), 2.86 (t, $J=6.0$ Hz, 2H), 2.64--2.72 (q, $J=7.5$ Hz, 2H), 1.18 (t, $J=7.5$ Hz, 3H). Anal. Calcd. for C$_{18}$H$_{20}$N$_2$O$_2$ (296.36): C 72.95; H 6.80; N 9.45. Found: C 72.75; H 6.72; N 9.48.

4-tert-Butyl-N-(7-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl) benzamide (2c)—Yield 75%, m.p. 209.1°C to 211.1°C; $^1$HNMR (CDCl$_3$) $\delta$ (ppm): 7.73 (d, $J=8.4$ Hz, 2H), 7.47 (d, $J=8.1$ Hz, 2H), 7.09 (s, 1H, -NH, D$_2$O exchange), 6.84 (d, $J=9.0$ Hz, 1H), 6.66 (dd, $J=2.7$, 1.8 Hz, 1H), 4.02 (s, 2H), 3.27 (t, $J=5.7$ Hz, 2H), 2.93 (t, $J=6.0$ Hz, 2H), 1.33 (s, 9H). Anal. Calcd. for C$_{20}$H$_{24}$N$_2$O$_2$ (324.42): C 74.04; H 7.46; N 8.64. Found: C 73.82; H 7.46; N 8.46.

N-(7-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)-4-methoxybenzamide (2d)—Yield 65%, m.p. 192.5°C to 194.3°C; $^1$HNMR (CDCl$_3$) $\delta$ (ppm): 8.12 (d, $J=8.4$ Hz, 2H), 3.09 (t, $J=5.8$ Hz, 2H), 3.42 (t, $J=6.0$ Hz, 2H), 3.89 (s, 3H), 4.29 (s, 2H), 6.89 (s, 1H), 6.99 (dd, $J=2.7$, 1.8 Hz, 1H), 7.18 (d, $J=9.0$ Hz, 1H), 7.76 (d, $J=8.1$ Hz, 2H). Anal. Calcd. for C$_{17}$H$_{18}$N$_2$O$_3$ 0.095 EtOAc: C 66.57; H 5.92; N 9.13. Found: C 66.93; H 6.28; N 8.62.

N-(7-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-methoxybenzamide (2e)—Yield 40%, m.p. 190.5°C to 192.3°C; $^1$HNMR (CDCl$_3$) $\delta$ (ppm): 7.42--7.51 (m, 3H), 7.14 (d, $J=6.0$ Hz, 2H), 3.82 (s, 3H), 2.84 (t, $J=6.0$ Hz), 2.65 (t, $J=5.8$ Hz, 2H). Anal. Calcd. for C$_{17}$H$_{18}$N$_2$O$_3$ 0.089 EtOAc (306.19): C 66.69; H 5.93; N 9.15. Found: C 66.93; H 6.28; N 8.62.

N-(7-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-methoxybenzamide (2f)—Yield 50%, m.p. 197.3°C to 199.4°C; $^1$HNMR (CDCl$_3$) $\delta$ (ppm): 2.67 (t, $J=5.7$ Hz, 2H,C$_4$-H), 2.89 (t, $J=6.0$ Hz, 2H,C$_3$-H), 3.84 (s, 3H, OCH$_3$ group), 4.21 (s, 2H C$_1$-H), 6.58 (d, $J=9.0$ Hz, 2H,C$_6$, C$_8$-H), 6.91 (d, $J=3.0$ Hz, 1H,C$_5$-H), 7.04 (s, 1H, -NH$_2$, D$_2$O exchange), 7.14--7.28 (m, 2H, C$_3'$, C$_5'$-H), 7.54 (d, $J=8.1$ Hz, 2H, C$_4'$, C$_6'$-H). Anal. Calcd. for C$_{17}$H$_{18}$N$_2$O$_3$ 0.095 EtOAc (306.72): C 66.57; H 5.92; N 9.13. Found: C 66.93; H 6.28; N 8.62.

2-Ethyl-N-(7-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl) benzamide (2g)—Yield 49%, m.p. 215.3°C to 215.7°C; $^1$HNMR (CDCl$_3$) $\delta$ (ppm): 7.41 (d, $J=8.1$ Hz, 2H), 7.23--7.30 (m, 2H), 7.21 (s, 1H, -NH$_2$, D$_2$O exchange), 6.88 (d, $J=3.0$ Hz, 1H), 6.65 (d, $J=3.0$ Hz, 1H), 6.48 (d, $J=9.0$ Hz, 1H), 4.19 (s, 2H), 3.49 (t, $J=5.7$ Hz, 2H), 3.02 (t, $J=6.0$ Hz, 2H),...
2.78–2.86 (q, J=7.5 Hz, 2H), 1.24 (t, J=7.5 Hz, 3H). Anal. Calcd. for C_{18}H_{20}N_{2}O_{2} 0.105 EtOAc: C 70.74; H 6.6; N 9.17. Found: C 70.51; H 7.08; N 8.29.

4-Ethyl-N-(6-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl) benzamide (2h)— Yield 55%, m.p. 220.1°C to 221.6°C; \(^1\)HNMR (CDCl\(_3\)) \(\delta\) (ppm): 7.62 (d, J=8.1 Hz, 2H), 7.16 (d, J=8.1 Hz, 2H), 7.09 (s, 1H, -NH, D\(_2\)O exchange), 6.84 (d, J=8.4 Hz, 1H), 6.56 (dd, J=2.7, 5.4 Hz, 1H), 6.43 (d, J=2.1, 1.8 Hz, 1H), 3.92 (s, 2H), 3.18 (t, J=5.7 Hz, 2H), 2.84 (t, J=6.0 Hz, 2H), 2.61–2.72 (q, J=7.5 Hz, 2H), 1.21 (t, J=7.5 Hz, 3H). Anal. Calcd. for C_{18}H_{20}N_{2}O_{2} 0.05EtOAc (300.78): C 71.88; H 6.70; N 9.31. Found: C 72.13; H 6.79; N 9.31.

4-Ethyl-N-(8-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl) benzamide (2i)— Yield 63%, m.p. 218.5°C to 220.4°C; \(^1\)HNMR (CDCl\(_3\)) \(\delta\) (ppm): 7.65 (d, J=8.1 Hz, 2H), 7.17 (d, J=8.1 Hz, 2H), 7.09 (s, 1H, -NH, D\(_2\)O exchange), 6.79 (d, J=8.4 Hz, 1H), 6.58 (dd, J=2.7, 5.4 Hz, 1H), 6.35 (d, J=2.1, 1.8 Hz, 1H), 3.94 (s, 2H), 3.18 (t, J=5.7 Hz, 2H), 2.86 (t, J=6.0 Hz, 2H), 2.64–2.72 (q, J=7.5 Hz, 2H), 1.18 (t, J=7.5 Hz, 3H). Anal. Calcd. for C_{18}H_{20}N_{2}O_{2} (296.36): C 72.95; H 6.80; N 9.45. Found: C 72.79; H 6.69; N 9.28.

N,N’-(3,4-dihydroisoquinoline-2,8(1H)-diyl)bis(4-ethylbenzamide) (2j)— Yield 50%, m.p. 113.2°C to 116.4°C; \(^1\)HNMR (CD\(_3\)OD): \(\delta\) 7.96 (brs, 1H), 7.81 (d, J=8.1 Hz, 2H), 7.69 (d, J=7.8 Hz, 2H), 7.33 (d, J=7.5 Hz, 1H), 7.25 (d, J=8.1 Hz, 2H), 7.21 (d, J=8.1 Hz, 2H), 7.17 (s, 1H, -NH, D\(_2\)O exchange), 7.01 (d, J=7.5 Hz, 1H), 4.25 (s, 2H), 3.36 (t, J=6.0 Hz, 2H), 3.07 (t, J=5.1 Hz, 2H), 2.62–2.73 (m, 4H), 1.26 (tt, J=7.5, 7.8 Hz, 6H). Anal. Calcd. for C_{27}H_{29}N_{3}O_{2} (427.54): C 75.85; H 6.84; N 9.83. Found: C 75.59; H 6.81; N 9.82.

N-(8-amino-3,4-dihydroisoquinolin-2(1H)-yl)-4-ethylbenzamide (2k)— Yield 45%, m.p. 223.5°C to 224.8°C; \(^1\)HNMR (CD\(_3\)OD): \(\delta\) 7.75 (d, J=9.0 Hz, 2H), 7.31 (d, J=8.1 Hz, 2H), 6.93 (d, J=7.8 Hz, 2H), 7.17 (s, 1H, -NH, D\(_2\)O exchange), 7.01 (d, J=7.5 Hz, 1H), 4.25 (s, 2H), 3.36 (t, J=6.0 Hz, 2H), 3.07 (t, J=5.1 Hz, 2H), 2.62–2.73 (m, 4H), 1.26 (tt, J=7.5, 7.8 Hz, 6H). Anal. Calcd. for C_{18}H_{21}N_{3}O 0.015 EtOAc (296.71): C 72.89; H 6.78; N 13.76. Found: C 72.87; H 6.75; N 13.76.

4-Amino-N-(7-bromo-3,4-dihydroisoquinolin-2(1H)-yl) benzamide (2l)— Yield 54%, m.p. 177.8°C to 179.2°C; \(^1\)HNMR (CD\(_3\)OD): \(\delta\) 7.59 (d, J=8.7 Hz, 2H), 7.26 (d, J=5.7 Hz, 2H), 7.13 (s, 1H, -NH, D\(_2\)O exchange), 7.06 (d, J=8.1 Hz, 1H), 6.66 (dd, J=9.0 Hz, 2H), 4.03 (s, 2H), 3.15 (t, J=6.0 Hz, 2H), 3.02 (t, J=6.0 Hz, 2H), 2.67–2.74 (q, J=7.8, 7.5 Hz, 2H), 1.25 (t, J=7.8 Hz, 3H). Anal. Calcd. for C_{16}H_{16}BrN_{3}O 0.025 EtOAc (348.44): C 55.49; H 4.66; N 12.34. Found: C 55.15; H 4.63; N 12.06.

4-(Ethylbenzamido)-1,2,3,4-tetrahydroisoquinolin-7-yl 4-ethylbenzoate (2m)— Yield 60%, m.p. 195.8°C to 198.2°C; \(^1\)HNMR (CD\(_3\)OD): \(\delta\) 7.74 (d, J=8.7 Hz, 2H), 7.26 (d, J=5.7 Hz, 2H), 7.13 (s, 1H, -NH, D\(_2\)O exchange), 7.06 (d, J=8.1 Hz, 1H), 6.66 (d, J=9.0 Hz, 2H), 4.03 (s, 2H), 3.15 (t, J=6.0 Hz, 2H), 3.02 (t, J=6.0 Hz, 2H). Anal. Calcd. for C_{27}H_{28}N_{3}O_{3} (428.52): C 55.68; H 6.59; N 6.54. Found: C 75.41; H 6.37; N 6.52.
General procedure (Scheme 2) synthesis of substituted tetrahydroisoquinolines (THIQs) (3a–3l)—The aminating agent, 2, 4-Dinitrophenyl hydroxylate (13) was prepared following the reported procedure [33] and was used to make the substituted isoquinoline dinitrophenoxy salts as reported [33]. The salts were obtained after adding diethyl ether to the reaction mixture after completion, filtering the resulting suspension to yield yellow solid.

General procedure for the synthesis of ylides—Dry THF (10 mL) was added to the substituted isoquinoline dinitrophenoxy salts and the resulting suspension was stirred at ambient temperature for 10 min. Et$_3$N (2 eq) was added to the reaction mixture and stirred well. After 15 min. the substituted acid chlorides/sulfonyl chlorides (1.5 eq) were added and the reaction mixture was stirred at ambient temperature for 3 hours. Heating the reaction mixture at 70°C for 1 hr. helps in complete conversion in some reactions, but in many instances is not necessary. For isoquinolines having –NH$_2$ or –OH substituents, heating resulted in the formation of major amounts of bis-acylated products, hence avoided. TLC (100% ethyl acetate) revealed the product formation. Reaction mixture was quenched with saturated sodium bicarbonate solution and the compounds extracted with dichloromethane (50 mL), dried over sodium sulfate, filtered and solvent evaporated. The crude compounds were used as such for the next step without further purification.

General procedure for the synthesis of substituted tetrahydroisoquinolines—Absolute ethanol (10 mL) was added to the Ylides prepared by the above procedure, cooled to 0°C and stirred for 15 min. Sodium borohydride (8 eq.) was added in one portion to the reaction and stirred further at 0°C for 3 h to 5 h. TLC with hexane:ethyl acetate (1:1) as eluent showed a new spot corresponding to the product. Reaction was stopped, quenched by addition of water (3 mL), ethanol evaporated, brine (20 mL) was added and extracted using dichloromethane. The organic layer collected, dried over sodium sulfate, filtered and solvent evaporated. The residue thus obtained was subjected to CombiFlash chromatography using 0% to 100% hexane:ethylacetate gradient.

4-(tert-butyl)-N-(5-Methoxy-3,4-dihydroisoquinolin-2(1H)-yl) benzamide (3a)—Yield 82%; m.p. 191°C to 193°C; $^1$HNMR (CDCl$_3$) δ (ppm): 7.62 (d, J=8.7 Hz, 2H), 7.37 (d, J=8.7 Hz, 1H), 7.09 (s, (br), 1H, NH), 7.07 (t, J=7.8 Hz, 1H), 6.65 (d, J=7.8 Hz, 1H), 6.58 (d, J=7.8 Hz, 1H), 4.09 (s, 2H), 3.75 (s, 3H), 3.271 (t, J=6 Hz, 2H), 2.83 (t, J=6 Hz, 2H), 1.24 (s, 9H). Anal. Calcd. for C$_{21}$H$_{26}$N$_2$O$_2$. 0.15 EtOAc: C 71.72, H 7.45, N 7.97; Found C 71.95, H 7.44, N 7.50.

4-(tert-butyl)-N-(5-Hydroxy-3,4-dihydroisoquinolin-2(1H)-yl) benzamide (3b)—Yield 55%; m.p. 233°C; $^1$HNMR (CDCl$_3$) δ (ppm): 7.76-7.38 (dd, J=6.3, 1.5 Hz, 2H), 7.49-7.46 (m, 2H), 6.89 (m, J=7.5 Hz, 1H), 6.71 (d, J=7.5 Hz, 1H), 6.45 (d, J=7.2 Hz, 1H), 3.93 (s, 2H), 3.036 (t, J=6.3 Hz, 2H), 2.38 (t, J=6 Hz, 2H), 1.34 (s, 9H). Anal. Calcd. for C$_{20}$H$_{24}$N$_2$O$_2$: C 74.04, H 7.46, N 8.64; Found C 73.92, H 7.43, N 8.51.

N,N’-(3,4-Dihydroisoquinoline-2,5(1H)-diyl)bis(4-ethylbenzamide) (3c)—Yield 5%; m.p. 216°C to 218°C; $^1$HNMR (CDCl$_3$) δ (ppm): 7.74 (d, J=8.4 Hz, 2H), 7.65-7.60 (m,
3H), 7.26 (d, J=8.4 Hz), 7.17-7.12 (m, 3H), 6.835 (d, J=7.5 Hz, 1H), 4.09 (s, 2H), 3.23 (t, 2H), 2.82 (t, J=6 Hz, 2H), 2.67-2.57 (m, 4H), 1.22-1.14 (m, 6H).

**N-(5-Acetamido-3,4-dihydroisoquinolin-2(1H)-yl)-4-ethylbenzamide (3d)—** Yield 60%; m.p. 295°C to 297°C; ¹H NMR (CD$_3$OD) δ (ppm): 7.73-7.62 (d, J=8.4 Hz, 2H), 7.33 (d, J=8.1 Hz, 2H), 7.26-7.14 (m, 2H), 7.0 (d, J=6.9 Hz, 1H), 4.10 (s, 2H), 3.19 (t, J=6.3 Hz, 2H), 2.95 (t, J=6 Hz, 2H), 2.7 (q, J=7.8 Hz, 2H), 2.15 (s, 3H), 1.25 (t, J=7.8 Hz, 3H). Calcd. for C$_{20}$H$_{23}$N$_{3}$O$_{2}$: C 71.19, H 6.87, N 12.45; Found C 71.10, H 6.97, N 11.53.

**N-(5-(Benzyloxy)-3,4-dihydroisoquinolin-2(1H)-yl)-4-(tert-butyl) benzamide (3e) —** Yield 52%; m.p. 179°C to 181°C; ¹H NMR (CDCl$_3$) δ (ppm): 7.70 (d, J=8.7 Hz, 2H), 7.45-7.29 (m, 7H), 7.12 (t, J=7.8 Hz, 1H), 6.78 (d, J=7.8 Hz, 1H), 6.66 (d, J=7.8 Hz, 1H), 5.08 (s, 2H), 4.18 (s, 2H), 3.33 (t, J=6.3 Hz, 2H), 2.99 (t, J=6 Hz, 2H), 1.32 (s, 9H). Anal. Calcd. for C$_{27}$H$_{30}$N$_{2}$O$_{2}$: C 78.23, H 7.29, N 6.76; Found C 78.13, H 7.20, N 6.61.

**4-Ethyl-N-(5-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl) benzamide (3f)—** Yield 32%; m.p. 218°C to 220°C; ¹H NMR (CDCl$_3$) δ (ppm): 7.75 (d, J=8.1 Hz, 2H), 7.29-7.25 (m, 2H), 6.92 (t, J=7.5 Hz, 1H), 6.72 (d, J=8.4 Hz, 1H), 6.65 (d, J=2.4 Hz), 4.00 (s, 2H), 3.12 (t, J=5.7 Hz, 2H), 2.74-2.67 (q, J=7.6 Hz, 2H), 3.5 (t, J=6 Hz, 2H), 1.26 (t, J=7.6 Hz, 3H). Anal. Calcd. for C$_{18}$H$_{20}$N$_{2}$O$_{2}$: C 71.88, H 6.70, N 9.31; Found C 71.48, H 6.89, N 9.06.

**4-Ethyl-N-(7-methoxy-3,4-dihydroisoquinolin-2(1H)-yl) benzamide (3g)—** Yield 55%; m.p. 197°C; ¹H NMR (CDCl$_3$) δ (ppm): 7.68 (d, J=8.4 Hz, 2H), 7.26-7.23 (m, 2H), 6.77-6.73 (dd, J=8.4, 2.4 Hz, 1H), 6.55 (d, J=2.4 Hz), 4.18 (s (br), 2H), 3.77 (s, 3H), 3.34 (t, J=5.7 Hz, 2H), 2.98 (t, J=6 Hz, 2H), 2.72-2.64 (q, J=7.5 Hz, 2H), 1.24 (t, J=7.8 Hz, 3H). Anal. Calcd. for C$_{29}$H$_{23}$N$_{2}$O$_{2}$: C 73.52, H 7.14, N 9.03; Found C 73.71, H 7.16, N 8.90.

**Methyl-2-(4-ethylbenzamido)-1,2,3,4-tetrahydroisoquinoline-6-carboxylate (3h) —** Yield 37%; m.p. 137°C to 139°C; ¹H NMR (CDCl$_3$) δ (ppm): 7.68 (d, J=7.5 Hz, 2H), 7.26-7.23 (m, 2H), 7.06 (d, J=8.4 Hz, 1H), 6.77-6.73 (dd, J=8.4, 2.4 Hz, 1H), 6.55 (d, J=2.4 Hz), 4.18 (s (br), 2H), 3.77 (s, 3H), 3.34 (t, J=5.7 Hz, 2H), 2.75 (t, J=6 Hz, 2H), 2.60 (t, J=6 Hz, 2H).

**N-(5,8-Dibromo-3,4-dihydroisoquinolin-2(1H)-yl)-4-ethylbenzamide (3i) —** Yield 61%; m.p. 170°C; ¹H NMR (CDCl$_3$) δ (ppm): 7.72 (d, J=7.8 Hz, 2H), 7.34-7.25 (m, 4H), 4.18 (s (br), 2H), 3.34 (t, J=6 Hz, 2H), 3.038 (t, J=6 Hz, 2H), 2.73-2.65 (q, J=7.8 Hz, 2H), 1.24 (t, J=7.5 Hz, 3H). Anal. Calcd. for C$_{18}$H$_{18}$Br$_{2}$N$_{2}$O: C 49.34, H 4.14, N 6.39; Found C 49.56, H 4.19, N 6.25.

**4-Ethyl-N-(5-methoxy-3,4-dihydroisoquinolin-2(1H)-yl) benzamide (3j)—** Yield 52%; m.p. 163°C; ¹H NMR (CDCl$_3$) δ (ppm): 7.68 (d, J=8.4 Hz, 2H), 7.22-7.261 (m, 2H), 7.14 (t, J=8.1 Hz, 1H), 6.72 (d, J=8.1 Hz, 1H), 6.65 (d, J=7.5 Hz), 4.2 (s (br), 2H), 3.82 (s, 3H), 3.35 (t, J=6.3 Hz, 2H), 2.92 (t, J=6.3 Hz, 2H), 2.63-2.71 (q, J=7.8 Hz, 2H), 1.23 (t, J=7.8 Hz, 3H). Anal. Calcd. for C$_{19}$H$_{22}$N$_{2}$O$_{2}$: 0.05 EtOAc: C 72.49, H 7.04, N 8.90; Found C 72.73, H 6.89, N 8.20.
2-(4-Ethylbenzamido)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (3k)—
Yield 18%; m.p. 251°C to 253°C; 1HNMR (CD3OD) δ (ppm): 7.84-7.76 (m, 4H), 7.34 (d, J=7.8 Hz, 2H), 7.21 (d, J=8.1 Hz, 1H), 4.27 (s, 2H), 3.34-3.30 (m, 2H), 3.17-3.15 (m, 2H), 2.75-2.67 (q, J=7.5 Hz, 2H), 1.25 (t, J=7.5 Hz, 3H).

2-(4-Methoxyphenylsulfonamido)-1,2,3,4-tetrahydroisoquinolin-5-yl-4-methoxybenzene-sulfonate (3l)—
Yield 27%; m.p. 182°C to 183°C; 1HNMR (CDCl3) δ (ppm): 7.80-7.77 (m, 2H), 7.69 (d, J=7.8 Hz), 7.380 (s, 1H, NH), 7.24 (m, 2H), 7.067 (d, J=8.7 Hz), 4.22 (s, 2H), 3.89 (s, 3H), 3.31 (t, J=6.0 Hz, 2H), 3.07(t, J=5.7 Hz, 2H), 2.71-2.63 (q, J=7.8 Hz, 2H), 1.22 (t, J=7.8 Hz, 3H). Anal. Calcd. for C23H24N2O7S2: C 54.75, H 4.79, N 5.55; Found C 54.60, H 4.80, N 5.35.

4.1.8 General procedure (Scheme 3) synthesis of substituted tetrahydroisoquinolines (THIQs) (4a–4f)—The respective commercially available starting materials (tetrahydroisoquinolines) were purchased and treated with NaNO2 to obtain tetrahydroisoquinoline-N-Oxides followed by the reduction using Zn-Acetic acid to obtain the N-Amino tetrahydroisoquinolines. The resulting compounds were used as such for the next reaction without further purification.

4.1.9 General procedure for the synthesis of substituted tetrahydroisoquinolines—To an ice-cooled solution of N-amino tetrahydroisoquinolines (0.5 mmol) in anhydrous tetrahydrofuran (5 mL) containing triethylamine (1.5 mmol) was added substituted acid chlorides (0.76 mmol). The mixture was allowed to proceed for 4 h at room temperature. After completion of the reaction (monitored by TLC), it was quenched by adding 30 mL of saturated aqueous sodium bicarbonate solution. Extraction with dichloromethane (2 mL × 35 mL), drying over anhydrous sodium sulfate and removal of the solvent in vacuo gave the crude product, which was purified on Combiflash chromatography using ethyl acetate: hexane (3:2 v/v) as an eluent to yield the desired products.

N-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)-2-ethylbenzamide (4a)—Yield 38%; m.p. 162°C to 167°C; 1HNMR (CDCl3) δ (ppm): 7.45-7.17 (m 6H), 6.97 (s, 1H), 4.19 (s, 2H), 3.35-3.31 (m, 2H), 3.12, t, J=5.4 Hz, 1H), 2.85-2.77 (q, J=7.5 Hz, 2H), 1.25 (t, J=7.5 Hz, 3H).

N-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-4-ethylbenzamide (4b)—Yield 46%; m.p. 224°C to 225°C; 1HNMR (CD3OD) δ (ppm): 7.89 (d, J=8.1 Hz, 2H), 7.39 (d, J=8.4 Hz, 2H), 6.85 (s, 1H), 6.89 (s, 1H), 4.71 (s, 2H), 3.89-3.85 (m, 2H), 3.25 (t, J=6.3 Hz, 2H), 2.77-2.69 (q, J=7.5 Hz, 2H), 1.26 (t, J=7.5 Hz, 3H).

4-Ethyl-N-(1-isopropyl-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)benzamide (4c)—Yield 44%; m.p. 162°C to 163°C; 1HNMR (CD3OD) δ (ppm): 7.58 (d, 2H, J=8.4 Hz), 7.20 (d, 2H, J=8.1 Hz), 6.16 (m, 2H), 3.86 (s, 3H), 3.84 (s, 3H), 3.69 (d, 1H, J=6.6 Hz), 3.45-3.39 (m, 1H), 3.32-3.26 (m, 1H), 2.82-2.77 (m, 2H), 2.66 (q, 2H, J=7.8 Hz), 1.97-1.91 (m, 1H), 1.27-1.18 (m, 3H), 1.13 (d, 3H, J=6.9 Hz), 0.99 (d, 3H, J=6.6 Hz).
N-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)-4-ethylbenzamide (4d)—Yield 28%; Sticky solid; $^1$HNMR (CDCl$_3$) $\delta$ (ppm): 7.69 (d, J=8.1 Hz, 2H), 7.44-7.41 (m, 2H), 7.28-7.20, m(3H), 4.20 (s, 2H), 3.34-3.31 (m, 2H), 3.09 (t, J=6.0 Hz, 2H), 2.72-2.64 (q, J=7.5 Hz, 2H), 1.23 (t, J=7.8 Hz, 3H).

N-(6-Chloro-3,4-dihydroisoquinolin-2(1H)-yl)-4-ethylbenzamide (4e)—Yield 42%; m.p. 205°C to 206°C; $^1$HNMR (CDCl$_3$) $\delta$ (ppm): 7.68 (d, 2H, J=7.5 Hz), 7.25-7.11(m, 4H), 6.949 (1H, J=8.7 Hz), 4.16 (s, 2H), 3.30 (m, 2H), 3.02 (m, 2H), 2.68 (q, 2H, J=7.5 Hz), 1.23 (t, 3H, J=7.5 Hz).

Methyl-2-(4-ethylbenzamido)-6-((4-ethylbenzoyl)oxy)-1,2,3,4-tetrahydroisoquinoline-1-carboxylate (4f)—Yield 12%; m.p. 150°C to 152°C; $^1$HNMR (CDCl$_3$) $\delta$ (ppm): 8.14 (m, 3H), 7.71 (d, J=7.8 Hz, 2H), 7.46 (d, J=8.4 Hz, 1H), 7.34-7.25 (m, 3H), 7.04-7.01 (m, 2H), 5.15 (s, 1H), 3.77 (s, 3H), 3.39-3.31 (m, 2H), 2.98-2.93 (m, 2H), 2.78-2.66 (m, 4H), 1.31-1.22 (m, 6H).

**Antiproliferative activity studies**

The antiproliferative activities of substituted Tetrahydro isoquinolines 2a–2m, 3a–3l and 4a–4f (a total of 31 compounds) were evaluated at the Southern Research Institute (SRI, Birmingham, Alabama, USA) according to the procedure reported previously [34]. The compounds were screened against human ER (+) MCF-7 (breast), ER (−) MDA-MB-231 (breast), and Ishikawa (endometrial) cancer cell lines in comparison to tamoxifen (TAM), Raloxifene (RAL) and 4-hydroxytamoxifen (4-OHT).

**Material**

Human MCF-7 and MDA-MB-231 breast cancer cell lines were purchased from the NCI. The human Ishikawa endometrial cancer cell line was purchased from Sigma Aldrich. All three cell lines were cultured in phenol red-free RPMI-1640 (Hyclone) (500 mL) supplemented with L-glutamine-dipeptide (Hyclone) (5 mL), and 10% fetal bovine serum (Atlanta Biologicals) (50 mL).

**Method**

The cell lines were cultured and treated with compounds under study including the standard TAM ranging from 0.01 nM to 100,000 nM concentration in the presence of 10 nM estradiol using the previous reported method [35]. The results expressed as IC$_{50}$ (inhibitory concentration of 50%) were the averages of three data points for each concentration and were calculated using GraphPad Prism 4.0.

**Molecular modeling studies**

Docking method—The crystal structures of ER$\alpha$-4-OHT complex (PDB: 3ERT), ER$\beta$-RAL complex (PDB: QKN) and Tubulin-Taxol complex (PDB: 1JFF) whose coordinates were obtained from RCSB Protein Data Bank were used as a template to dock the active THIQs of present study. The crystal structures were imported into Sybyl-X 1.3 [36] modeling suite and using structure preparation tool, Chain A (ER$\alpha$-4-OHT and ER$\beta$-RAL), Chain B (Tubulin-TA1) were extracted, hydrogen atoms were added, MMFF94s force fields...
and MMFF94 charges were assigned to the atoms and energy minimized. The 3D structures of the substituted THIQs along with the co-crystallized ligands, 4-Hydroxytamoxifen (OHT), Raloxifene (RAL) and Taxol (TA1) were generated by Sybyl sketch and saved as single molecular file (sdf). The conformer ensembles of all the compounds to be docked were generated using OMEGA v2.4.6, OpenEye Scientific Software [37,38] prior to docking. OMEGA ensures that low strain energy conformations were retained in the ensemble. Since the complexes in the present study have bound ligands (OHT, RAL, TA1 respectively), HYBRID v3.0.1 of OEDocking [39,40] was chosen as the appropriate docking method for our studies. The dock resolution was set to ‘High’ to get the best results. The scoring function used in this process to evaluate the poses in HYBRID is HYBRID_Chemgauss4 [41]. It uses Gaussian-smoothed potentials to measure the complementary nature of ligand poses within the active site.

Docking studies—The X-ray structure of Ligand Binding Domain (LBD) of estrogen receptors has provided a better way to understand the ER binding site and that of β chain of Tubulin-Taxol complex to understand the Taxol binding domain. The validation of the docking poses of the bound ligands (antagonists) in individual crystal structures was done using OEdocking application, HYBRID [41] after generating the receptors using “Make Receptor version 3.0.1” module in OEdocking. The re-docking of the co-crystallized ligands has been undertaken to make sure that the bound conformations of the ligands (OHT, RAL, TA1) are reproduced by the selected docking method. Best 10 poses were retrieved and were identical with the original poses of the cognate ligands in the crystal structures with root mean square deviation (rmsd) values between them being <2 Å, a criterion often used for the correct bound structure prediction and validation.

Results and Discussion

Chemistry

Several substituted tetrahydroisoquinolines 2a–2m, 3a–3l and 4a–4f (a total of 31 compounds) were prepared according to three different procedures as shown in Schemes 1, 2 and 3. Compounds 2a–2m were synthesized following the Scheme 1. The aminating agent 10 was prepared using a reported procedure [32]. The amino salts of ring substituted 2-aminoisoquinolinium mesitylenesulfonates of general structure 11 used in the present study were prepared by the reaction of substituted isoquinolines and the aminating agent 10 as previously reported [31]. Reaction of 11 with corresponding substituted acylating agents (acyl chlorides) afforded N-ylides 12a–2m as stable crystalline solids. Sodium borohydride reduction of N-ylides 12a–2m in absolute ethanol furnished the title compounds 2a–2m in fair to good yields. Compounds 3a–3l were synthesized following the Scheme 2. The aminating agent 13 was prepared using a reported procedure [33]. The amino salts of ring substituted 2-aminoisoquinolinium compounds of general structure 14 were obtained with the reaction of the substituted isoquinolines and the aminating agent 13 in CH$_3$CN heated at 50°C for 24 hours. Without further purification, the salts were used to prepare the N-ylides by reaction with substituted acyl/sulfonyl chlorides. Final reduction of the ylides with sodium borohydride in absolute ethanol yielded the desired THIQs 3a–3l in moderate yields. Compounds 4a–4f were synthesized following the Scheme 3. N-Oxidation of commercially
available ring substituted THIQs followed by the reduction of the NO group using standard zinc/acetic acid led to the synthesis of N-amino THIQs. Acylation reaction of the isolation of N-amino THIQs with substituted acyl chlorides in the presence of base (Et₃N) yielded the desired substituted THIQs 4a–4f in low to moderate yields.

**Antiproliferative activity**

*In vitro* antiproliferative activity of compounds 2–4 were evaluated against human MDA-MB-231 (ER negative breast carcinoma cell line), MCF-7 (ER positive breast cancer cell line) and Ishikawa (endometrial) cancer cell lines at concentration ranging from 0.01 nM to 100,000 nM in the presence of 10 nM estradiol (E2) using CellTiter-Glo assay (E2 was used for competitive growth inhibitory studies). As shown in Table 1, compounds 2b, 2i, and 3g. (IC₅₀=0.2 μg/mL, 0.08 μg/mL; 0.61 μg/mL, 0.09 μg/mL; 0.25 μg/mL, 0.11 μg/mL) against MCF-7 and Ishikawa cell lines, in comparison to TAM (IC₅₀=3.99 μg/mL, 7.87 μg/ml). (Note: IC₅₀ is the concentration of test drug where a 50% reduction is observed in cell growth compared to the untreated control after a 72 h period of exposure to test drug). This may be due to the differential affinity and binding levels of the ligand structural features to the ER receptors in the MCF-7 and Ishikawa cell lines. However, to prove the point, the expression of ER receptors by western blot is under study. Compounds bearing hydroxyl (-OH) substituents at ⁷th position (2b) and ⁸th position (2i) proved to be very active of the series in this cell line and exhibit higher antiproliferative activity against MCF-7 cell line based on IC₅₀ value (Figure 1). However when the free hydroxyl group in compound (2b) was capped with a methyl group leading to compound (3g), the activity decreased marginally. However, the substituents at the ⁷th position seem to be an ideal location for further manipulations of the lead compound (1). Compound (4d) with a cyano (CN) substitution at the ⁷th position showed moderate activity (IC₅₀=1.28 μg/mL). Similarly, the ethyl substitution at the para position of the aryl-acyl ring leads to better activity than other substituents in that position and other positions on the ring.

The ER (−) MDA-MB-231 breast cancer cell line constitutes an original model for identifying the ER-independent mechanisms of TAM antiproliferative effects [42,43]. Thus, in the present study the antiproliferative activity of compounds 2–4 against human ER (−) MDA-MB-231 breast cancer cell lines were also investigated to know their mechanism of action (Figure 2). The results showed that compounds 2b, 2i and 3g (IC₅₀=0.13 μg/mL, 1.36 μg/mL, 0.23 μg/mL) were more potent than TAM (IC₅₀=7.85 μg/mL) shown in Table 1. Furthermore, compound 2i shows reasonable selectivity towards MCF-7 cell lines than MDA-MB-231 (IC₅₀=0.61 μg/mL, 1.36 μg/mL respectively), making us believe that this particular compound may be acting as ER inhibitor. Compounds (2b) and (3g) may also inhibit cell proliferation via ER-independent mechanism in comparison to TAM. Our recently published work [31] indicates that compound (2b) acts as a potent microtubule-destabilizing agent by holding static the microtubule network, thereby preventing mitosis. Cell viability studies on similar compounds, tetrahydropyridines (THPs) made in our laboratory indicated that the dosage system used in the experiments could not lead to non-specific high toxicity effect of these compounds against normal cells. Similar studies on the tetrahydroisoquinolines (THIQs) are under investigation.
Evaluation of the antiproliferative activity of these compounds against human Ishikawa endometrial cell line were revealed that compounds 2a–2e, 2i, 2j–2m, 3g, 3i, 3j, 4d and 4e were more potent than TAM IC$_{50}$=7.87 μg/mL (Table 1). These results indicate some of the compounds in the present study may lower the risk of developing uterine cancer based upon the IC$_{50}$ value in comparison with TAM [35] (Figure 3).

**Molecular modeling studies**

The top scoring conformations of the THIQs under present study were collected by docking the conformer ensemble (generated by OMEGA [37,38] on ER$_{\alpha}$ and ER$_{\beta}$ and Tubulin-Taxol receptors (Figures 4–6) show the preference for ER$_{\alpha}$ as the ligands fit better in the bigger ligand binding pocket of ER$_{\alpha}$. These studies also give us an idea of the probable bioactive conformations and binding mode of the newly synthesized ring substituted THIQs which would assist in further optimization studies. The best compound (2b) showed hydrogen bonding interaction with Arg: 394(A) residue in the ER$_{\alpha}$-4-OHT complex. Similarly a strong hydrogen bonding with THR: 276(B) was observed for this compound in the tubulin-taxol complex. No hydrogen bonds were observed when compound (2b) was docked into the ER$_{\beta}$-RAL complex and the scores were relatively low compared to other molecules in the study. This may be an indication for the selectivity of the compound (2b) and other similar active compounds towards ER$_{\alpha}$ and also its role as a microtubule-destabilizing activity as reported previously by us [31].

**Discussion**

The antiproliferative activity of 31 new ring substituted THIQs (2, 3 and 4 series) were synthesized based on our lead structure (1) reported earlier, using three different synthetic approaches and were evaluated on MCF-7, MDA-MB-231, and Ishikawa cell lines. Their activities were compared with the reference drugs in the market, tamoxifen, 4-hydroxytamoxifen and raloxifene. In particular, the focus was on to examine the effects of the position and nature of substituents on the ring systems of lead THIQ (1). Compounds 2b and 3g with hydroxyl and methoxy substitutions on the 7th position of the THIQ phenyl ring proved to be more active than the lead structure (1). The other active compound in the series was compound (2i) where the hydroxyl substitution is on the 8th position of the THIQ phenyl ring. A look at the poses adapted by compound (2i) in all three docking experiments reveal that this compound scored lower than the compounds 2b and 3g. A hydrogen bonding interaction of its hydroxyl group with THR: 276(B) is observed in 1JFF but no hydrogen bonding with Arg: 394(A) was observed in 3ERT. Substitutions on the THIQ’s aliphatic six membered rings (compounds 4c and 4f) proved to be completely inactive. Similarly, bis methoxy substitutions at 6th and 7th positions of the THIQ aromatic ring yielded inactive compounds. A comparison of the ethyl, t-butyl, methoxy substitutions on the acyl ring showed that the ethyl substituent at the 4-position (para) is the most optimal substitution for activity enhancement. Bis-acylated compounds 2j, 2m, 3c were less active whereas, 3d, 3l, and 4f were completely inactive. The lack of directed hydrogen bonding in the of compounds 2j, 2m, 3c, 3d, 3l, 4c and 4f might be the reason to their biological inactivity.
Conclusion

Ring substituted THIQs based on the lead compound (1) were synthesized using three different synthetic methods in moderate yields and fully characterized. Their anti-proliferative activities against ER(+) MCF-7 and ER(−) MDA-MB-231 breast cancer cell lines and Ishikawa cell lines were determined and compared to that of the standard drugs in the market tamoxifen, 4-hydroxytamoxifen and raloxifene. THIQs containing hydroxyl and methoxy substituents on the 7th position of the THIQ phenyl ring and ethyl substituent in the 4th position of the acyl ring proved to be promising and showed more activity compared to the lead compound (1). However compound containing a hydroxyl substitution at the 8th position (2i) showed significant selectivity towards ER(+) MCF-7 breast cancer cell lines compared to ER(−) MDA-MB-231 cell lines indicating that this particular compound may be acting via ER dependent mechanism while compounds (2b) and (3g) may be acting via ER independent mechanisms. Our recent studies have indeed showed that compound (2b) is a potent microtubule-destabilizing agent. Pose predictions and docking scores were compared for the active and inactive THIQs in the present study. The docking scores (Hybrid_Chemgauss scores) for the active THIQs were consistently higher than the inactive compounds. Within the active compounds, the scores agree with the experimental findings. Hydrogen bonding interactions between the amino acid residues of the receptors in the active site and the compounds containing OH substituents on the THQ phenyl ring were observed.

Acknowledgments

We are grateful to the National Center for Research Resources and the National Institute of Minority Health and Health Disparities of the National Institutes of Health through Grant Number 8 G12MD007582-28 and Grant Number 1P20 MD006738-01. We are also grateful to Dr. Michael J. Roberts, Cell Biology and Immunology, Southern Research Institute, Birmingham, AL, for testing cytotoxicity on three cell lines and OpenEye Scientific Software, Inc., Santa Fe, NM for free Academic License.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians. 2017; 67:7–30. [PubMed: 28055103]
2. Osborne CK, Schiff R, Arpino G, Lee AS, Hilsenbeck VG. Endocrine responsiveness: Understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005; 14:458–465. [PubMed: 16236516]
3. Johnston S. Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br J Cancer. 2004; 90:15–18.
4. Tamoxifen for early breast cancer: An overview of the randomized trials early breast cancer trialists' Collaborative Group. Lancet. 1998; 351:1451–1467. No authors listed. [PubMed: 9605801]
5. Jordan VC. The role of tamoxifen in the treatment and prevention of breast cancer. Curr Probl Cancer. 1992; 16:129–176. [PubMed: 1582240]
6. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: Eighth Cain memorial award lecture. Cancer Res. 1990; 50:4177–4189. [PubMed: 2194650]
7. Ettinger B. Overview of estrogen replacement therapy: A historical perspective. Proc Soc Exp Biol Med. 1998; 217:2–5. [PubMed: 9421200]
8. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, et al. Selective estrogen receptor modulators: Discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 2004; 64:1522–1533. [PubMed: 14973112]
9. Osborne CK, Wakeling A, Nicholson RI. An oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004; 90:2–6.

10. Sui M, Huang Y, Park BH, Davidson NE, Fan W. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res. 2007; 67:5337–5344. [PubMed: 17545614]

11. El Amouri H, Vessières A, Vichard D, Top S, Gruselle M, et al. Syntheses and affinities of novel organometallic-labeled estradiol derivatives. A structure-affinity relationship. J Med Chem. 1992; 35:3130–3135. [PubMed: 1507201]

12. Ahmed N, Dubuc C, Rousseau J, Bénard F, Van Lier JE. Synthesis, characterization, and estrogen receptor binding affinity of flavone-indole and furan-estradiol conjugates. Bioorg Med Chem Lett. 2007; 17:3212–3216. [PubMed: 17379515]

13. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995; 87:746–750. [PubMed: 7563152]

14. Bowler J, Lilley TJ, Pittam JD, Wakeling AE. Novel steroidal pure antiestrogens. J Endocrinol. 1989; 54:71–99.

15. Jordan VC. The strategic use of antiestrogens to control the development and growth of breast cancer. Cancer. 1992; 70:977–982. [PubMed: 1638467]

16. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997; 138:863–870. [PubMed: 9048584]

17. Seeger H, Huober J, Wallwiener D, Mueck AO. Inhibition of human breast cancer cell proliferation with estradiol metabolites is as effective as with tamoxifen. Horm Metab Res. 2004; 36:277–280. [PubMed: 15156405]

18. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, et al. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998; 90:1371–1388. [PubMed: 9747868]

19. Phillips DH, Venitt S. Safety of prophylactic tamoxifen. Lancet. 1993; 341:1485–1486.

20. Jordan VC. Tamoxifen: A most unlikely pioneering medicine. Nat Rev Drug Discov. 2003; 2:205–213. [PubMed: 12612646]

21. Chesworth R, Zawistoski MP, Lefker BA, Renaud J, Bischoff SF, et al. Estrogen receptor modulators: Identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands. J Med Chem. 2003; 46:2945–2957. [PubMed: 12825935]

22. Lin HR, Safo MK, Abraham DJ. Identification of a series of tetrahydroisoquinoline derivatives as potential therapeutic agents for breast cancer. Bioorg Med Chem Lett. 2007; 17:2581–2589. [PubMed: 17337183]

23. Renaud J, Bischoff SF, Buhl T, Floersheim P, Fournier B, et al. Estrogen receptor modulators: Identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands. J Med Chem. 2003; 46:2945–2957. [PubMed: 12825935]

24. Renaud J, Bischoff SF, Buhl T, Floersheim P, Fournier B, et al. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands. J Med Chem. 2005; 48:364–379. [PubMed: 15658851]

25. Atmaca H, Uzunoglu S. Anti-angiogenic effects of trabectedin (yondelis; ET-743) on human breast cancer cells. Eur Cytokine Netw. 2014; 25:1–7. [PubMed: 24941346]

26. Kumar P, Rawat A, Keshari AK, Singh AK, Maity S, et al. Antiproliferative effect of isolated isoquinoline alkaloid from Mucuna pruriens seeds in hepatic carcinoma cells. Nat Prod Res. 2015; 30:460–463. [PubMed: 25774560]

27. Lane JW, Estevez A, Mortara K, Callan O, Spencer JR, et al. Antitumor activity of tetrahydroisoquinoline analogues 3-epi-jorumycin and 3-epi-renieramycin G. Bioorg Med Chem Lett. 2006; 16:3180–3183. [PubMed: 16632360]

28. Aickgoz E, Guven U, Duzagac F, Uslu R, Kara M, et al. Enhanced G2/M arrest, caspase related apoptosis and reduced E-cadherin dependent intercellular adhesion by trabectedin in prostate cancer stem cells. PLoS One. 2015; 10:e0141090. [PubMed: 26485709]
29. Leese MP, Jourdan F, Dohle W, Kimberley MR, Thomas MP, et al. Steroidomimetic Tetrahydroisoquinolines for the design of new microtubule disruptors. ACS Med Chem Lett. 2012; 3:5–9. [PubMed: 22247790]

30. Gangapuram M, Jean R, Mazzio E, Badisa R, Eyunni S, et al. Substituted tetrahydroisoquinolines as microtubule-destabilizing agents in triple negative human breast cancer cells. Anticancer Res. 2016; 36:5043–5052. [PubMed: 27798863]

31. Gangapuram M, Eyunni S, Redda KK. Synthesis and pharmacological evolution of tetrahydroisoquinolines as anti-breast cancer agents. J Cancer Sci Ther. 2014; 6:161–169. [PubMed: 25525496]

32. Tamura Y, Minamikawa J, Miki Y, Matsugashita S, Ikeda M. A novel method for heteroaromatic N-imines. J Org Chem. 1972; 40:4133–4135.

33. Legault C, Charette AB. Highly efficient synthesis of O-(2, 4-Dinitrophenyl)-hydroxylamine. Application to the synthesis of substituted N-Benzoyliminopyridinium Ylides. J Org Chem. 2003; 68:7119–7122. [PubMed: 12946163]

34. Crouch SP, Kozlowski R, Slater KJ, Fletcher J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods. 1993; 160:81–88. [PubMed: 7680699]

35. Suresh VK, Madhavi G, Redda KK. In-vitro antiproliferative activity of new tetrahydroisoquinolines (THIQs) on Ishikawa cells and their 3d pharmacophore models. Lett Drug Des Discov. 2014; 11:428–436. [PubMed: 25506297]

36. Khairy M, El-Safty SA, Ismael M. Mesoporous nanomagnet supercaptors for selective heme-proteins from human cells. Chem Commun. 2012; 48:10832–10834.

37. Hawkins PC, Skillman AG, Warren GL, Ellingson BA, Stahl MT. Conformer generation with OMEGA: Algorithm and validation using high quality structures from the protein databank and Cambridge structural database. J Chem Inf Model. 2010; 50:572–584. [PubMed: 20235588]

38. McGann, M. OEDocking 3.0.1. OpenEye Scientific Software; Santa Fe, NM:

39. Jug G, Anderluh M, Tomasic T. Comparative evaluation of several docking tools for docking small molecule ligands to DC-SIGN. J Mol Model. 2015; 21:164. [PubMed: 26040678]

40. McGann M. FRED and HYBRID docking performance on standardized datasets. J Comput Aided Mol Des. 2012; 26:897–906. [PubMed: 22669221]

41. McGann MR, Almond HR, Nicholls A, Grant JA, Brown FK. Gaussian docking functions. Biopolymers. 2003; 68:76–90. [PubMed: 12579581]

42. Colletta AA, Benson JR, Baum M. Alternative mechanisms of action of anti-oestrogens. Breast Cancer Res Treat. 1994; 31:5–9. [PubMed: 7981456]

43. Butta A, MacLennan K, Flanders KC, Sacks NP, Smith I, et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 1992; 52:4261–4264. [PubMed: 1322240]
Figure 1.
In vitro antiproliferative activity of selective compounds against ER (+) MCF-7 cell line.
Figure 2.

*In vitro* antiproliferative activity of selective compounds against ER (−) *MDA-MB-231* cell line.
Figure 3.
*In vitro* antiproliferative activity of selective compounds against Ishikawa cell line.
Figure 4.
Top scoring binding pose of the most active substituted THIQ (2b) at the active site of ERα-4-OHT complex (3ERT).
Figure 5.
Top scoring binding pose of the most active substituted THIQ (2b) at the active site of ERβ-RAL complex (1QKN).
Figure 6.
Top scoring binding pose of the most active substituted THIQ (2b) at the active site of alpha-beta tubulin taxol.
Scheme 1.
**Reaction Conditions:** (i) DMF, 0 °C, 45 min, (ii) 70 % HClO₄, p-dioxane, 0 °C, 45 min, (iii) Substituted isoquinoline, dry CH₂Cl₂, 0 °C, 5h, (iv) 4-substituted acyl/sulfonyl chlorides, dry THF, 70 °C, 12h, (v) NaBH₄, abs. EtOH, 7 h; R = OH, Br, NH₂; X = CO, SO₂; R¹ = 4-C₂H₅, 3-OCH₃, 2-OCH₃, 2-C₂H₅
Scheme 2.

**Reaction Conditions:** (i) Et$_3$N, RT, 2 hours, (ii) NH$_2$.NH$_2$. H$_2$O, CH$_2$Cl$_2$. MeOH,0 °C, (iii) CH$_3$CN, 50 °C,(iv) Et$_3$N, THF, 25 °C, (v) NaBH$_4$. EtOH, RT; X = CO, SO$_2$ R= 5-OCH$_3$, 5-OH, 5-NHCOCH$_3$, 5-NH-CO-C$_6$H$_4$-C$_2$H$_5$, 5-OCH$_2$-C$_6$H$_5$, 7-OCH$_3$, 7-COOCH$_3$, 5,8-di-Br, 6-COOH, 5-OSO$_2$-C$_6$H$_4$-OCH$_3$; R$_1$ =4-C(CH$_3$)$_3$.C$_6$H$_4$. 4-C$_2$H$_5$.C$_6$H$_4$. 4-OCH$_3$.C$_6$H$_4$
Scheme 3.

**Reaction Conditions:** i) NaNO$_2$, H$_2$O, 0 °C, ii) Zn, CH$_3$COOH, iii) Acyl Chlorides, Et$_3$N, THF; R = 7-CN, 6,7-di-OCH$_3$, 6-CI, 6-OCO-C$_6$H$_4$-C$_2$H$_5$; R' = 4-C$_2$H$_5$-C$_6$H$_4$, R'' = 1-CH(CH$_3$)$_2$, 1-COOCH$_3$
Table 1
Antiproliferative activity of substituted Tetrahydroisoquinolines.

| Code | Structure | IC50 μg/mL |
|------|-----------|------------|
|      |           | Ishikawa   | MCF-7 | MDA-MB-231 |
| 1    | ![Structure of compound 1](image1) | 0.01 | 0.43 | 0.37 |
| 2a   | ![Structure of compound 2a](image2) | 1.15 | 3.50 | 6.01 |
| 2b   | ![Structure of compound 2b](image3) | 0.08 | 0.2 | 0.13 |
| 2c   | ![Structure of compound 2c](image4) | 0.95 | 2.3 | 4.7 |
| 2d   | ![Structure of compound 2d](image5) | 0.99 | >29.83 | 25.17 |
| 2e   | ![Structure of compound 2e](image6) | 0.31 | 1.86 | 1.71 |
| Code | Structure | IC50 μg/mL | Ishikawa | MCF-7 | MDA-MB-231 |
|------|-----------|------------|----------|-------|-------------|
| 2f   | ![Image](image1.png) | >29.83     | >29.83   | >29.83 |
| 2g   | ![Image](image2.png) | >29.64     | >29.64   | >29.64 |
| 2h   | ![Image](image3.png) | 22.38      | >29.64   | >29.64 |
| 2i   | ![Image](image4.png) | 0.09       | 0.61     | 1.36   |
| 2j   | ![Image](image5.png) | 2.74       | 9.35     | 9.71   |
| 2k   | ![Image](image6.png) | 0.60       | 2.23     | 16.82  |
| 2l   | ![Image](image7.png) | 1.09       | 2.80     | 9.86   |

*J Cancer Sci Ther. Author manuscript; available in PMC 2018 February 07.*
| Code | Structure | IC50 μg/mL |
|------|-----------|------------|
|      |           | Ishikawa   | MCF-7 | MDA-MB-231 |
| 2m   | ![Structure](114x611_to_320x678) | 0.13 | 2.53 | 2.78 |
| 3a   | ![Structure](134x513_to_300x596) | >33.84 | >33.84 | >33.84 |
| 3b   | ![Structure](134x415_to_300x498) | 10.96 | 7.92 | 10.25 |
| 3c   | ![Structure](137x263_to_297x400) | 9.45 | 4.59 | 6.1 |
| 3d   | ![Structure](138x142_to_296x248) | >33.74 | >33.74 | >33.74 |
| Code | Structure | IC50 μg/mL |
|------|-----------|------------|
|      |           | Ishikawa   | MCF-7 | MDA-MB-231 |
| 3e   | ![Structure](image1) | >41.45 | >41.45 | >41.45 |
| 3f   | ![Structure](image2) | 9.93 | 18.61 | 15.61 |
| 3g   | ![Structure](image3) | 0.11 | 0.25 | 0.23 |
| 3h   | ![Structure](image4) | 8.64 | 15.21 | 16.14 |
| 3i   | ![Structure](image5) | 0.84 | 2.34 | 1.71 |
| 3j   | ![Structure](image6) | 6.34 | 7.38 | 10.46 |
| Code | Structure | IC50 μg/mL |
|------|-----------|------------|
| 3k   | ![Structure 3k](image) | >32.44 >32.44 >32.44 |
| 3l   | ![Structure 3l](image) | >50.46 >50.46 >50.46 |
| 4a   | ![Structure 4a](image) | >30.54 26.45 >30.54 |
| 4b   | ![Structure 4b](image) | >34.10 >34.10 >34.10 |
| 4c   | ![Structure 4c](image) | 15.02 >38.25 >38.25 |
| 4d   | ![Structure 4d](image) | 0.9 1.28 1.76 |
| Code | Structure | IC50 μg/mL | Ishikawa | MCF-7 | MDA-MB-231 |
|------|-----------|------------|----------|-------|------------|
| 4e   | ![Structure 4e](image1) | 0.98 | 2.49 | 3.74 |
| 4f   | ![Structure 4f](image2) | 45.56 | >48.65 | >48.65 |
|      | Tamoxifen | 7.87 | 3.99 | 7.85 |
|      | Raloxifene-Hydrochloride | 10.53 | 0.98 | 11.21 |
|      | 4-Hydroxy Tamoxifen | 3.57 | 0.95 | 6.51 |